UnknownPHASE1, PHASE2NCT02528526

Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Zurich
Principal Investigator
Pierre Alain, Clavien
University Hospital Zurich, Visceral Surgery
Intervention
OXY111A(drug)
Enrollment
69 enrolled
Eligibility
18 years · All sexes
Timeline
20142016

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02528526 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials